Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Portfolio Pulse from Lara Goldstein
Terran Biosciences discovers new psilocybin compounds, MindMed's LSD study for anxiety treatment enrolls and doses 100 participants, and PharmAla receives Health Canada's approval for MDMA treatment. UK Parliament debates accelerating psychedelics research and psilocybin rescheduling.
May 23, 2023 | 11:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AdvisorShares Psychedelics ETF (PSIL) opened at $1.76 on May 22, with a yearly price range between $4.35 and $1.65.
The opening price of the AdvisorShares Psychedelics ETF (PSIL) and its yearly price range provide a general overview of the ETF's performance. However, this information alone does not indicate a clear short-term price direction for the ETF.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
MindMed's Phase 2b clinical trial on LSD compound MM-120 for Generalized Anxiety Disorder is over 50% enrolled and dosed.
MindMed's progress in its Phase 2b clinical trial for LSD compound MM-120 targeting Generalized Anxiety Disorder indicates positive momentum for the company. As the trial progresses and more participants are enrolled, it could potentially lead to positive results, which would be beneficial for the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80